IDYA EBITDA | IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

IDEAYA Biosciences, Inc. ebitda for the quarter ending 2026-06-30 was -$121.59M, a change of -$33.49M year-over-year.
IDEAYA Biosciences, Inc. ebitda for the quarter ending 2026-03-31 was -$107.84M, a change of -$24.06M year-over-year.
IDEAYA Biosciences, Inc. ebitda for the quarter ending 2025-12-31 was -$93.87M, a change of $49.67M year-over-year.
IDEAYA Biosciences, Inc. ebitda for the quarter ending 2025-09-30 was $109.15M, a change of $175.45M year-over-year.
IDEAYA Biosciences, Inc. ebitda for fiscal 2025 was -$156.61M, a change of $167.98M from fiscal 2024.
IDEAYA Biosciences, Inc. ebitda for fiscal 2024 was -$324.59M, a change of -$192.64M from fiscal 2023.
IDEAYA Biosciences, Inc. ebitda for fiscal 2023 was -$131.95M, a change of -$71.55M from fiscal 2022.
IDEAYA Biosciences, Inc. ebitda for fiscal 2022 was -$60.4M, a change of -$11.86M from fiscal 2021.

Available history: 2017-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$121.59M	-$122.29M	$700,000.00	(m)	(m)	$866.00K*	-$88.21M*	(m)	$108.69M	(m)	$0.00*
2026-03-31	Reported	-$107.84M	-$108.54M	$700,000.00	(m)	-1644.15%	$967.00K	-$75.17M	(m)	$95.73M	(m)	$0.00
2025-12-31	Reported	-$93.87M	-$94.57M	$700,000.00	(m)	-862.90%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$109.15M	$108.45M	$700,000.00	(m)	(m)	$42.00K*	$142.21M*	(m)	$82.99M	(m)	$0.00*
2025-06-30	Reported	-$88.11M	-$88.81M	$700,000.00	(m)	(m)	$663.00K*	-$62.47M*	(m)	$74.23M	(m)	$0.00
2025-03-31	Reported	-$83.79M	-$84.39M	$600,000.00	(m)	(m)	$1.33M	-$60.34M	(m)	$70.89M	(m)	$0.00
2024-12-31	Reported	-$143.54M	-$144.14M	$600,000.00	(m)	-2050.94%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$66.29M	-$66.89M	$600,000.00	(m)	(m)	$457.00K*	-$49.23M*	(m)	$57.15M	(m)	$0.00
2024-06-30	Reported	-$64.33M	-$64.93M	$600,000.00	(m)	(m)	$973.00K*	-$32.88M*	(m)	$54.53M	(m)	$0.00
2024-03-31	Reported	-$50.42M	-$51.02M	$600,000.00	(m)	(m)	$1.32M	-$43.81M	(m)	$42.80M	(m)	$0.00
2023-12-31	Reported	-$41.22M	-$41.92M	$700,000.00	(m)	-1052.73%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$32.93M	-$33.53M	$600,000.00	(m)	(m)	$603.00K*	-$30.17M*	(m)	$33.70M	(m)	$0.00
2023-06-30	Reported	-$32.11M	-$32.71M	$600,000.00	(m)	(m)	$884.00K*	-$33.46M*	(m)	$29.18M	(m)	$0.00
2023-03-31	Reported	-$25.68M	-$26.28M	$600,000.00	(m)	-326.03%	$43.00K	-$27.84M	(m)	$27.86M	(m)	$0.00
2022-12-31	Reported	-$25.84M	-$26.44M	$600,000.00	(m)	-643.59%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	$1.26M	$660,000.00	$600,000.00	(m)	(m)	$1.10M*	-$24.17M*	(m)	$22.37M	(m)	$0.00
2022-06-30	Reported	-$22M	-$22.5M	$500,000.00	(m)	(m)	$1.94M*	-$19.99M*	(m)	$22.80M	(m)	$0.00
2022-03-31	Reported	-$13.72M	-$14.22M	$500,000.00	(m)	-121.10%	$401.00K	-$19.65M	(m)	$19.66M	(m)	$0.00
2021-12-31	Reported	-$17.97M	-$18.37M	$400,000.00	(m)	-605.03%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$11.21M	-$11.71M	$500,000.00	(m)	(m)	$458.00K*	-$12.47M*	(m)	$15.50M	(m)	$0.00
2021-06-30	Reported	-$10.65M	-$11.05M	$400,000.00	(m)	(m)	$578.00K*	-$12.93M*	(m)	$14.98M	(m)	$0.00
2021-03-31	Reported	-$8.74M	-$9.14M	$400,000.00	(m)	-120.78%	$1.00M	-$13.72M	(m)	$11.57M	(m)	$0.00
2020-12-31	Reported	-$4.88M	-$5.28M	$400,000.00	(m)	-46.53%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$4.7M	-$5M	$300,000.00	(m)	(m)	$245.00K*	$90.21M*	(m)	$10.03M	(m)	$0.00
2020-06-30	Reported	-$12.19M	-$12.59M	$400,000.00	(m)	(m)	(m)	-$13.61M*	(m)	$8.60M	(m)	$0.00
2020-03-31	Reported	-$12.18M	-$12.48M	$300,000.00	(m)	(m)	(m)	-$9.54M	(m)	$9.03M	(m)	$0.00
2019-12-31	Reported	-$10.82M	-$11.32M	$500,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$11.32M	-$11.62M	$300,000.00	(m)	(m)	$82.00K*	-$10.55M*	(m)	$8.92M	(m)	$0.00
2019-06-30	Reported	-$10.94M	-$11.24M	$300,000.00	(m)	(m)	$449.00K*	-$10.27M*	(m)	$8.86M	(m)	$0.00
2019-03-31	Reported	-$9.79M	-$10.09M	$300,000.00	(m)	(m)	$606.00K	-$9.79M	(m)	$8.00M	(m)	$0.00
2018-12-31	Reported	-$8.83M	-$9.13M	$300,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$13.43M	-$13.63M	$200,000.00	(m)	(m)	$1.00M*	-$8.69M*	(m)	$12.54M	(m)	$0.00
2018-06-30	Reported	-$7.37M	-$7.57M	$200,000.00	(m)	(m)	(m)	(m)	(m)	$6.43M	(m)	$0.00

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$156.61M	-$159.31M	$2.7M	(m)	-71.61%	$2.37M	-$71.10M	(m)	$314.70M	(m)	$0.00
2024-12-31	Reported	-$324.59M	-$326.98M	$2.39M	(m)	-4636.97%	$3.86M	-$247.58M	(m)	$294.67M	(m)	$0.00
2023-12-31	Reported	-$131.95M	-$134.43M	$2.48M	(m)	-564.26%	$2.37M	-$115.22M	(m)	$129.51M	(m)	$0.00
2022-12-31	Reported	-$60.4M	-$62.5M	$2.1M	(m)	-118.59%	$3.44M	-$87.17M	(m)	$89.54M	(m)	$0.00
2021-12-31	Reported	-$48.54M	-$50.27M	$1.73M	(m)	-173.73%	$2.64M	-$55.78M	(m)	$58.16M	(m)	$0.00
2020-12-31	Reported	-$33.96M	-$35.34M	$1.38M	(m)	-173.83%	$493.00K	$55.46M	(m)	$39.70M	(m)	$0.00
2019-12-31	Reported	-$43.03M	-$44.27M	$1.25M	(m)	(m)	$1.35M	-$39.31M	(m)	$34.32M	(m)	$0.00
2018-12-31	Reported	-$35.53M	-$36.42M	$886,000.00	(m)	(m)	$1.71M	-$27.62M	(m)	$31.75M	(m)	$0.00
2017-12-31	Reported	-$14.05M	-$14.44M	$391,000.00	(m)	(m)	$1.76M	-$12.22M	(m)	$12.38M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Organon & Co. (OGN)	United States	$3.603B	17.03
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27
Amylyx Pharmaceuticals, Inc. (AMLX)	United States	$3.361B	-13.15
Enliven Therapeutics, Inc. (ELVN)	United States	$3.307B	-35.07
Arcutis Biotherapeutics, Inc. (ARQT)	United States	$3.303B	115.47
ACADIA PHARMACEUTICALS INC (ACAD)	United States	$3.823B	11.45
AbCellera Biologics Inc. (ABCL)		$3.879B	-14.59
Arcus Biosciences, Inc. (RCUS)	United States	$3.188B	-8.52
Dyne Therapeutics, Inc. (DYN)	United States	$3.084B	-7.09
Tango Therapeutics, Inc. (TNGX)	United States	$4.154B	-42.53